Virological failure and subsequent resistance profiles in individuals exposed to atazanavir.
Few data exist regarding the resistance profile in individuals receiving atazanavir. We found that ritonavir-boosted atazanavir is not associated with the development of primary genotypic resistance in individuals failing this combination, without previous protease inhibitor failure. It is rarely associated with the acquisition of primary mutations in individuals with previous protease inhibitor exposure. This is particularly important because of the increasing use of atazanavir monotherapy, and implies that treatment failure is caused by lack of potency.
Stebbing
Justin
J
Department of HIV Medicine, The Chelsea and Westminster Hospital, Imperial College School of Science, Technology and Medicine, London, UK.
Nathan
Bif
B
Jones
Rachael
R
McKenna
Alex
A
Powles
Tom
T
Bower
Mark
M
Holmes
Paul
P
Gazzard
Brian
B
Nelson
Mark
M
D000069446:Atazanavir Sulfate; D024921:Drug Resistance, Multiple, Viral; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D009842:Oligopeptides / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D019438:Ritonavir / Q000627:therapeutic use; D017211:Treatment Failure
D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate; D019438:Ritonavir